About the Authors

Penny L. Moore

Affiliations AIDS Virus Research Unit, National Institute for Communicable Diseases, Johannesburg, South Africa, University of the Witwatersrand, Johannesburg, South Africa

Nthabeleng Ranchobe

Affiliation AIDS Virus Research Unit, National Institute for Communicable Diseases, Johannesburg, South Africa

Bronwen E. Lambson

Affiliation AIDS Virus Research Unit, National Institute for Communicable Diseases, Johannesburg, South Africa

Elin S. Gray

Affiliation AIDS Virus Research Unit, National Institute for Communicable Diseases, Johannesburg, South Africa

Eleanor Cave

Affiliation AIDS Virus Research Unit, National Institute for Communicable Diseases, Johannesburg, South Africa

Melissa-Rose Abrahams

Affiliation Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa

Gama Bandawe

Affiliation Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa

Koleka Mlisana

Affiliation Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu Natal, Durban, South Africa

Salim S. Abdool Karim

Affiliation Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu Natal, Durban, South Africa

Carolyn Williamson

Affiliation Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa

Lynn Morris

lynnm@nicd.ac.za

Affiliations AIDS Virus Research Unit, National Institute for Communicable Diseases, Johannesburg, South Africa, University of the Witwatersrand, Johannesburg, South Africa

the CAPRISA 002 study and the NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI)

Competing Interests

The authors have declared that no competing interests exist.

Author Contributions

Conceived and designed the experiments: PLM ESG LM. Performed the experiments: PLM NR BEL EC. Analyzed the data: PLM NR BEL ESG EC LM. Contributed reagents/materials/analysis tools: MRA GB KM SSAK CW. Wrote the paper: PLM ESG CW LM. Conceived, implemented and led the CAPRISA 002 Acute Infection study: KM SSAK CW.